Anticancer Drugs: Prospects and Challenges
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 524
Special Issue Editor
Interests: chemical biology; natural products; cancer biology; tumor metabolism; signaling pathways
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The development of cancer-specific therapeutics has been limited because most healthy cells and cancer cells depend on common pathways. Nature, an expert craftsman of molecules, has generated an extensive array of bioactive molecular entities and supplied an enormous scaffold diversification for development into effectual drugs to treat cancer. Recent-day researchers are better equipped to carry out organic synthesis, phytochemical extraction, analysis, quality control, pharmacological, and toxicological evaluation. In view of the serious adverse effects associated with the use of current anticancer clinical drugs, the scientific community must continue its search for new leads (natural or synthetic active constituents) to treat various types/stages of cancer. Novel drug candidates are required, overcoming the lacunas pertinent to the use of current therapeutic agents. The present Special Issue aims to cover the recent developments of scientific merit in the arena of anticancer drugs either from natural or synthetic origin and formulations, providing insight into their current status in therapeutic pursuits. We welcome authors to submit their articles covering the theme at a diversified level from novel drug leads or known compounds with novel targets
Dr. Azhar Rasul
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- small molecules
- natural compounds
- signaling pathways
- cancer drug targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
